{"id":323481,"date":"2026-10-22T12:20:16","date_gmt":"2026-10-22T06:50:16","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=323481"},"modified":"2026-10-22T12:20:16","modified_gmt":"2026-10-22T06:50:16","slug":"global-pharma-franchise-sterile-injectables-and-anti-retroviral-ingredients-stocks-roadmap-sentinel-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/global-pharma-franchise-sterile-injectables-and-anti-retroviral-ingredients-stocks-roadmap-sentinel-list\/","title":{"rendered":"3 Global Pharma Franchise, Sterile Injectables and Anti-Retroviral Ingredients Stocks With a Strong Future Roadmap: Lupin, Gland Pharma and Laurus Labs"},"content":{"rendered":"

Lupin, Gland Pharma and Laurus Labs: ROE of 9.9% to 23.8% and FY22 to FY26 revenue CAGR of 8.5% to 15.0%. Prices as of 21 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The three export-focused pharma stocks to watch are Lupin, Gland Pharma and Laurus Labs. Their return on equity ranges from 9.9% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 15.0%. Lupin leads on both return on equity at 23.8% and revenue growth at 15.0% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n

Export-focused pharma stocks let investors follow companies that earn a large share of revenue from overseas customers. Lupin, Gland Pharma and Laurus Labs cover a global pharma franchise, sterile injectables and anti-retroviral ingredients.<\/p>\n

This list covers three export-focused pharma stocks with complete current figures: Lupin, Gland Pharma and Laurus Labs. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n